2,4,3'',5''-Tetramethoxystilbene acts as an inhibitor of human cytochrome P450 1B1 and has been seen to inhibit cell growth as well as induce apoptosis in cancer cells.
CYP1B1 is mainly an extrahepatic enzyme which oxidatively metabolizes both endogenous (steroids; eicosanoids) and exogenous xenobiotics such aspolyaromatic hydrocarbons. TMS is a potent and selective inhibitor of CYP1B1, with an IC50 of 6 nM. It is 50-fold selective for the inhibition of CYP1B1 versus CYP1A1, making it a useful tool to differentiate between various CYP450 families. In cultured human colon cancer cells, TMS induces apoptosis and inhibits cell growth with an IC50 of 0.8 μg/ml.
2,4,3',5'-Tetramethoxystilbene acts as an inhibitor of human cytochrome P450 1B1 and has been seen to inhibit cell growth as well as induce apoptosis in cancer cells.
ChEBI: 1-[2-(2,4-dimethoxyphenyl)ethenyl]-3,5-dimethoxybenzene is a stilbenoid.
Potent, selective and competitive inhibitor of cytochrome P450 1B1, an enzyme overexpressed in certain tumors (IC 50 = 6 nM). 50- and 520-fold selective over P450 1A1 and 1A2 respectively. Inhibits cancer cell growth in vitro .
To determine the contribution of CYP1B1 in development of hypertension in spontaneously hypertensive rats (SHR), the effect of TMS is examined on in SHR and WKY rats. Systolic BP steadily increases in SHR from 4 weeks of age. Starting from 8 weeks of age, daily injections of TMS reduce systolic BP in SHR to levels observed at the beginning of the experiment (207±7 vs. 129±2 mmHg). Systolic BP is not altered in WKY injected with TMS or its vehicle (129±7 vs. 127±4 mmHg) [1].
CYP1B1: 6 nM (IC50); CYP1B1: 3 nM (Ki); CYP1A1: 300 nM (IC50); CYP1A2: 3.1 μM (IC50)
